Blog
RSS FeedPosted by Michael Wonder on 07 Dec 2021
Zai Lab announces inclusion of Zejula (niraparib) in China’s National Reimbursement Drug List for first-line ovarian cancer
3 December 2021 - Zai Lab today announced that the National Reimbursement Drug List released by China’s National Healthcare Security Administration ...
Posted by Michael Wonder on 07 Dec 2021
China clears insurance coverage for Kainos Medicine’s HIV drug
6 December 2021 - A home-grown HIV treatment developed by Kainos Medicine and out-licensed to China’s Jiangsu Aidea Pharmaceuticals has ...
Posted by Michael Wonder on 07 Dec 2021
Ascletis announces inclusion in new catalogue of China National Reimbursement Drug List of Asclevir/Ganovo regimen, an all oral direct anti-HCV therapy
2 December 2021 - Ascletis Pharma today announces that its all-oral direct anti-hepatitis C virus Asclevir (ravidasvir)/Ganovo (danoprevir) regimen has been ...
Posted by Michael Wonder on 07 Dec 2021
BeiGene announces inclusion in the China National Reimbursement Drug List (NRDL) of tislelizumab in three new indications, Brukinsa (zanubrutinib) in one new indication, and the first listing for pamiparib
2 December 2021 - BeiGene today announced that three of its medicines have been added to the most recent National Reimbursement ...
Posted by Michael Wonder on 07 Dec 2021
Junshi Biosciences announces two additional indications for toripalimab included in China’s National Reimbursement Drug List
3 December 2021 - The only anti-PD-1 monoclonal antibody in the NRDL for melanoma and nasopharyngeal carcinoma. ...
Posted by Michael Wonder on 04 Dec 2021
Drug makers cut prices by 62% on average to get China state insurance listing
4 December 2021 - Pharmaceutical firms have agreed to cut prices by 61.7% on average for 67 medicines to be ...
Posted by Michael Wonder on 03 Dec 2021
TOT Biopharm announces NMPA granted marketing approval for Pusintin (TAB008, bevacizumab) in China
1 December 2021 - TOT Biopharm announced its self-developed Pusintin (TAB008, bevacizumab) has been officially granted approval by the National ...
Posted by Michael Wonder on 30 Nov 2021
Junshi Biosciences announces approval of supplemental new drug application by NMPA for toripalimab in combination with cisplatin and gemcitabine as first-line treatment for patients with locally recurrent or metastatic nasopharyngeal carcinoma
30 November 2021 - Fourth approved indication for toripalimab. ...
Posted by Michael Wonder on 30 Nov 2021
TRACON Pharmaceuticals reports regulatory approval of envafolimab in China
29 November 2021 - First approval of a subcutaneously administered checkpoint inhibitor. ...
Posted by Michael Wonder on 15 Nov 2021
Competing with, and learning from, China in the global pharmaceutical innovation race
15 November 2021 - President Joe Biden has promoted investment in technology based industries, including the life sciences, as a strategic ...
Posted by Michael Wonder on 23 Sep 2021
Innovent announces NMPA acceptance of a supplemental new drug application for sintilimab in combination with chemotherapy as first-line therapy for oesophageal squamous cell carcinoma
22 September 2021 - Innovent Biologics today announced that the National Medical Products Administration of China has accepted the supplemental new ...
Posted by Michael Wonder on 09 Sep 2021
Merck’s Keytruda (pembrolizumab) approved in China in combination with chemotherapy for first-line treatment of patients with locally advanced unresectable or metastatic oesophageal or gastro-oesophageal junction carcinoma
7 September 2021 - Keytruda is now approved for eight indications across five different types of cancer in China. ...
Posted by Michael Wonder on 06 Sep 2021
JW Therapeutics announces NMPA approval of relmacabtagene autoleucel injection in China
6 September 2021 - The first CAR-T product independently developed in China and approved as a Category 1 biologics product, and ...
Posted by Michael Wonder on 05 Sep 2021
CStone announces China's NMPA has accepted its new drug application for sugemalimab in the treatment of stage III NSCLC
2 September 2021 - Sugemalimab becomes the world’s first anti-PD-1/PD-L1 monoclonal antibody to significantly improve progression-free survival in patients with stage ...
Posted by Michael Wonder on 31 Aug 2021
Ligand’s Partner Gloria Biosciences receives approval in China for zimberelimab for the treatment of recurrent or refractory classical Hodgkin’s lymphoma
31 August 2021 - First regulatory approval of an OmniAb derived antibody. ...